Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | CARPALL and AMELIA: ongoing data for CAR-T in ALL

Sara Ghorashian • 2 Apr 2019
BSH 2019
Acute Lymphoblastic Leukemia Leukemia AUTO3 CAR-T Tisagenlecleucel
AMELIA CARPALL

We spoke to Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, about the CARPALL (NCT02443831) and AMELIA (NCT03289455) trials. CARPALL is looking at CD19 CAR-T for young patients with relapsed acute lymphoblastic leukemia (ALL), while AMELIA is investigating CD19/22 CAR T-cells (AUTO3) for the treatment of relapsed/refractory B-cell ALL. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Sara Ghorashian

Exciting updates in ALL and the value of novel immunotherapies
1:11
Exciting updates in ALL and the value of novel immunotherapies
Sara Ghorashian • 11 Dec 2022
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
3:18
Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALL
Sara Ghorashian • 11 Dec 2022
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
2:18
Analysis of real-world outcomes in patients with B-ALL receiving tisagenlecleucel
Sara Ghorashian • 11 Dec 2022
Managing relapse after CAR-T therapy in ALL
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals